Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE, Tsai TF
           Department of Pediatrics, Yonsei University College of Medicine, Seoul,
           Korea.
           Vaccine 1999 May 4;17(18):2259-64

        Attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been
        administered safely and effectively to more than 100 million children in
        China since 1988 and recently, licensure of the vaccine in Korea has
        been sought. In the first clinical evaluation of the vaccine outside of
        China, we monitored side effects in 84 children and evaluated antibody
        responses to a single dose given as primary JE vaccination in 68
        children, 1-3 years old (mean age 27 months). No significant adverse
        events were noted. Neutralizing antibodies (geometric mean titer [GMT]
        of 188) were produced in 96% of the 68 subjects. In 10 other children
        who previously had been immunized with two or three doses of inactivated
        JE vaccine, the booster administration of SA14-14-2 vaccine produced an
        anamnestic response in all, with a GMT of 3378. In a comparison group of
        25 children previously immunized with two doses of inactivated vaccine,
        neutralizing antibody titers were detected in 16 (64%). Viral specific
        IgM was detected in nine primary vaccinees (13%) but in others, IgM may
        have declined to undetectable levels in the four week postimmunization
        sample. Live attenuated SA14-14-2 JE vaccine is a promising alternative
        to the only commercially available JE vaccine for national childhood
        immunization programs in Asia.